GlassScriptPhysician profile
Emily Keber
NPI 1396580700
$1,911.34
in general payments reported to CMS, 2019-2025
21 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $475 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,911.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $291.51 | 2024-2025 | Rexulti |
| Abbvie INC. | $225.73 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $150.99 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $126.50 | 2024-2025 | Trintellix |
| Noven Therapeutics, LLC | $126.03 | 2024-2025 | Xelstrym |
| Vanda Pharmaceuticals INC. | $122.70 | 2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $113.96 | 2024-2025 | Ingrezza |
| Corium, LLC | $99.95 | 2024-2025 | Azstarys |
| Alkermes, INC. | $99.09 | 2025 | Aristada, Lybalvi |
| Tris Pharma INC | $82.83 | 2025 | Onyda Xr, Quillichew Er, Dyanavel Xr |
| Axsome Therapeutics, INC. | $71.57 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $62.66 | 2024-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $52.75 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $49.91 | 2024-2025 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $48.86 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $44.48 | 2025 | Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $42.26 | 2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $37.92 | 2024-2025 | Cobenfy |
| Tempus Ai, INC | $28.70 | 2024 | |
| Tms Neurohealth Centers INC. | $18.36 | 2025 | Tms Neurohealth Centers INC. |
| Supernus Pharmaceuticals, INC. | $14.58 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Keber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.